Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Names Hemophilia Drug as Newest Pipeline Candidate

Premium

Alnylam Pharmaceuticals announced this week that it has added ALN-APC, an siRNA-based treatment for hemophilia, to its formal drug-development pipeline.

Earlier this year, Alnylam CEO John Maraganore said that the company would select two new drug programs before the end of the year, and was considering several diseases, including thalassemia, hemophilia, and hereditary angioedema (GSN 5/12/2011).

The newest program targets protein C, a natural anticoagulant pathway. The drug candidate is designed to boost levels of thrombin generation and reduce frequency of bleeding in hemophiliacs.

“With the opportunity to measure clinically meaningful biomarkers in a phase I trial [of ALN-APC], we expect to achieve early human data followed by execution on what we believe are clear and rapid development and commercialization paths,” Alnylam CMO Akshay Vaishnaw said in a statement. “We anticipate advancing this program into clinical development in 2013."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.